Seikagaku Corporation
Seikagaku Corporation, a leading biopharmaceutical company based in Japan, has established itself as a key player in the field of regenerative medicine and orthopaedics since its founding in 1947. With its headquarters in Tokyo, Seikagaku operates extensively across Asia, Europe, and North America, focusing on the development and manufacturing of innovative products that enhance joint health and tissue regeneration. The company is renowned for its core offerings, including hyaluronic acid-based products, which are uniquely designed to treat osteoarthritis and promote joint function. Seikagaku's commitment to research and development has positioned it as a pioneer in the industry, achieving significant milestones such as the introduction of groundbreaking therapies that have transformed patient care. With a strong market presence and a dedication to advancing medical science, Seikagaku Corporation continues to lead the way in biopharmaceutical innovation.
DitchCarbon Score
How does Seikagaku Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Seikagaku Corporation's score of 31 is higher than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Seikagaku Corporation's reported carbon emissions
In 2023, Seikagaku Corporation, headquartered in Japan, reported total carbon emissions of approximately 22,721,000 kg CO2e for Scope 1 and 2, alongside significant Scope 3 emissions of about 57,262,000 kg CO2e. This data reflects the company's ongoing commitment to transparency in its environmental impact, although no specific reduction targets or initiatives have been documented. Over the past few years, Seikagaku's Scope 1 and 2 emissions have shown slight fluctuations, with figures of approximately 23,385,000 kg CO2e in 2022, 23,831,000 kg CO2e in 2021, 24,687,000 kg CO2e in 2020, and 25,478,000 kg CO2e in 2019. The company has not disclosed any Scope 3 emissions data prior to 2023. Despite the absence of formal reduction targets or climate pledges, Seikagaku Corporation's emissions data is independently sourced, ensuring reliability in its reporting. The company continues to navigate the complexities of carbon management within the biopharmaceutical industry, focusing on sustainability and environmental responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 8,441,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 14,945,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Seikagaku Corporation is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
